B+
Bull case
25%
Probability
Target price
$17.00
+25.9% vs current
INMD
InModeCNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$14.50
+7.4% vs current
B-
Bear case
30%
Probability
Target price
$11.50
-14.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+54.3
Score
AI commentary
This remains a cautious post-earnings monitoring memo, not a clean thesis upgrade. Primary-source confirmation improved the evidence base, but forward visibility is still weak and the deterministic prior still implies very high uncertainty. The initial market reaction was negative: using fetched price history, INMD closed at $14.40 on May 5, 2026, then $13.59 on May 6 after the release, before only partially recovering to $13.92 on May 7. That fits a read-through of revenue/guidance resilience being outweighed by margin compression, leadership turnover, and still-soft aesthetics demand. Trustworthy delayed analyst-revision evidence was thin, so missing revision data should be treated as an evidence gap, not a positive.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-05eventQ2 margin stabilization is now the key post-earnings proof pointHigh impact
Q1 2026 revenue rose 5% year over year to $82.0 million and management reiterated FY2026 revenue guidance of $365 million to $375 million, but GAAP operating margin fell to 12% from 20% and management said profitability was lower than expected while it reshapes sales teams in North America and Europe. The next decision point is whether revenue can hold while margins recover. [#6K-2026-05-06]
2026-09-30catalystRepurchase execution can cushion downside but is not a demand fixMedium impact
The board authorized a new repurchase program for up to about 10% of shares on March 13, 2026, and the May 6 earnings release said InMode had already repurchased 2.55 million shares for $34.8 million as of March 31 and $52.7 million year to date under the new 2026 program. That supports per-share value and signals balance-sheet confidence, but it does not by itself solve softer aesthetics demand or margin pressure. [#6K-2026-03-13][#6K-2026-05-06]
2026-12-31catalystA durable U.S. aesthetics recovery remains the real rerating requirementHigh impact
The 2025 Form 20-F said U.S. revenue fell 18.9% in 2025 due to slower demand for aesthetic procedures and a challenging financing market in the United States, while revenue outside the U.S. rose 14.5% on Europe and Asia strength. Q1 showed some U.S. improvement, but management still described the macro environment as challenging and demand as deferred. A sustained rerating likely needs clearer evidence that U.S. procedure demand and financing conditions are normalizing without further margin erosion. [#20F-2026-02-10][#6K-2026-05-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology